Topics in Critical and Intensive Care, Addiction Medicine, Mental Health, Substance Abuse, and Obesity

Dr. Edward Fisher received his BA in Biology and PhD in Pharmaceutical Sciences from Temple University, Philadelphia, Pennsylvania, and his BS in Pharmacy at Temple University College of Pharmacy. His current position is Professor and Dean, College of Pharmacy, Marshall B. Ketchum University,  Fullerton, California. 

Dr. Fisher has been granted tenure at three different universities. His first academic position was at Southwestern Oklahoma State University College of Pharmacy where he was promoted to Associate Professor. Subsequently, he went on to help start up three new colleges of pharmacy, Midwestern University-Glendale College of Pharmacy as Professor and Inaugural Department Chair of Pharmaceutical Sciences, The Daniel K Inouye College of Pharmacy, University of Hawaii at Hilo, as Professor and Associate Dean. 

He also served as the Director of the MS in Clinical Psychopharmacology program. His current position is Professor and Dean, College of Pharmacy, Marshall B. Ketchum University, 2575 Yorba Linda Blvd., Fullerton, California.

Dr Fisher is licensed as a pharmacist in Arizona and Pennsylvania, and has practiced in a variety of clinical settings. He has devised and presented over 100 continuing education seminars and innovative NSF sponsored short courses. He is a past National Secretary of Rho Chi, the only pharmacy honor society, and recipient of the National Rho Chi Advisor of the Year award. In addition to his administrative responsibilities, he currently plans to continue teaching in his areas of expertise which includes: substances of abuses, nutrition, and the pharmacotherapy of mental disorders. 

Professor of Intensive Care Medicine
University College London
London,UK

Head, Research Department of Clinical Physiology, Division of Medicine
Director, Bloomsbury Institute of Intensive Care Medicine
Editor-in-Chief, Intensive Care Medicine experimental (ICMx)
NIHR Senior Investigator 2009-2017
 

Mervyn Singer is Professor of Intensive Care Medicine at University College London, UK. He trained in medicine at St Bartholomew's Hospital Medical College, London and then undertook subsequent junior doctor posts in hospitals around the London area. He performed his doctorate research thesis developing a novel hemodynamic monitoring tool using esophageal Doppler ultrasonography; the subsequent technology (CardioQ) is now used in >30 countries worldwide. He then began formal critical care training in an academic rotation at University College London in 1989 and was appointed Professor in 2001. 

He is Director of the Bloomsbury Institute of Intensive Care Medicine and runs a research group totaling 15 people performing bench-to-bedside research. Specific interests include sepsis and multi-organ failure, tissue oxygenation, infection, novel diagnostics and monitoring. Funding comes from the Wellcome Trust, UK Medical Research Council, European Union, and UK National Institute of Health Research (NIHR) among others. He has published widely, with multiple papers in the New England Journal of Medicine, Lancet and JAMA. Apart from the above-mentioned esophageal Doppler monitor, he has developed a novel tissue PO2 monitor (gauging the adequacy of tissue perfusion) entering clinical trials in 2016, and a novel drug inducing a 'suspended animation' state intended for ischaemia-reperfusion injury that is scheduled to go into man also in 2016. He is also the clinical lead investigator of studies on novel diagnostics for sepsis and infection, and the first intensivist to be appointed a Senior Investigator by the NIHR. 

He lectures widely and has delivered four plenary lectures at the annual Congresses of the European Society of Intensive Care Medicine and the US Society of Critical Care Medicine. He has authored/edited several textbooks including the Oxford Textbook of Critical Care and the Oxford Handbook of Critical Care. He is currently Editor-in-Chief of Intensive Care Medicine Experimental (ICMx), co-chair of the new Sepsis Redefinitions Task Force, Council Member of the International Sepsis Forum, Critical Care Theme Lead of the NIHR Health Informatics Collaborative, and does 13 clinical on-call weeks per annum in the ICU.